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Symptomatic oesophageal cancer is usually advanced and the prognosis poor. Lethality of symptomatic oesophageal cancer has
motivated screening for these diseases earlier in their evolution, but reliable methods for early diagnosis remain elusive. We have
demonstrated that dysregulated expression of minichromosome maintenance (MCM) proteins 2–7 is characteristic of early epithelial
carcinogenesis, and that these key DNA replication initiation factors can be used as diagnostic markers for cervical and genito-urinary
tract cancer. In this study, we investigated whether minichromosome maintenance protein 5 (Mcm5) can be used to detect
oesophageal cancer cells in gastric aspirates. Two monoclonal antibodies raised against His-tagged human Mcm5 were used in a time-
resolved immunofluorometric assay to measure Mcm5 levels in cells isolated from gastric aspirates of 40 patients undergoing
gastroscopy for suspected or known oesophageal carcinoma or symptoms of dyspepsia. The test discriminated with high specificity
and sensitivity between patients with and without oesophageal cancer (85% sensitivity (95% confidence interval (CI)¼62–97%),
85% specificity (CI¼66–96%)), as demonstrated by the large area under the receiver operating characteristics curve (0.93 (95%
CI¼0.85–0.99)). Elevated levels of Mcm5 in gastric aspirates are highly predictive of oesophageal cancer. This simple test for
oesophageal cancer is readily automated with potential applications in primary diagnosis, surveillance and screening.
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The incidence of oesophageal cancer in Western societies is
increasing rapidly (Blot et al, 1991) and currently stands at
approximately 6 per 100000 in England and Wales (Office for
National Statistics England and Wales, 1999). It accounts for
about 6700 cancer-related deaths per year in the UK (Cancer
Research Campaign, 1998, 1999). Most patients are not candidates
for curative treatment as the symptoms associated with oesopha-
geal cancer predominantly arise when the tumour is at an
advanced stage. Without curative treatment, the overall mean
survival of patients with oesophageal cancer is 6 months, even
including those patients deemed suitable for curative treatment,
the overall survival is poor, about 5% at 5 years (Newnham et al,
2003).
However, when applied to patients with very early disease, the
latest chemotherapy regimes offer excellent results, and 5-year
survival for T1–2N0 disease is now greater than 80% (Urschel and
Vasan, 2003). Therefore, at present, the key to successful treatment
of oesophageal cancer is early diagnosis and there is consequently
great interest in the development of a screening test that will
identify patients with asymptomatic oesophageal malignant or
premalignant disease. Patients with Barrett’s oesophagus (Miros
et al, 1991), known to have a high risk of developing oesophageal
carcinoma, can be screened endoscopically, but this is time
consuming and of questionable effectiveness. An extension of
current endoscopic screening to include patients with gastro-
oesophageal reflux disease would have even less cost effectiveness,
even though this group is at increased risk of developing
oesophageal cancer (Iftikhar et al, 1992). Certain risk factors such
as cigarette smoking (Brown et al, 1994; Hu et al, 1994; Rolon et al,
1995), alcohol (Brown et al, 1994; Hu et al, 1994; Rolon et al, 1995)
and age (Office for National Statistics England and Wales, 1999)
are also associated with higher risk but again lack suitable
specificity to be useful as screening tools.
Population screening for squamous oesophageal carcinoma is
only practised where the incidence is high such as Japan and
China using techniques such as abrasive cytology, barium
oesophagography and fibreoptic oesophagoscopy (Riddell, 1996).
This is a labour-intensive approach requiring skilled cytopathol-
ogists, gastroenterologists and radiologists. Dysplasia and cancer
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ysurveillance by endoscopy and biopsy of Barrett’s patients in
Western populations is also undertaken, but with uncertain benefit
(Macdonald et al, 2000).
Despite advances in the molecular pathology of oesophageal
neoplasia, no useful clinical biomarkers have yet been identified
for diagnostic and screening applications. The initiation of DNA
replication represents a final and critical step in growth regulation
and lies downstream at the convergence point of growth regulatory
pathways (Williams and Stoeber, 1999). Proteins of the mini-
chromosome maintenance (MCM) family (minichromosome
maintenance protein 2–7, Mcm2–7) play a critical role (DNA
replicative helicase) in the initiation of DNA replication (Bell and
Dutta, 2002). We have previously demonstrated that dysregulation
of MCM proteins is an early event in epithelial carcinogenesis,
resulting in exfoliation of MCM-positive tumour cells, and have
used these novel biomarkers of growth in diagnostic screening
applications for cervical and genitourinary tract cancer (Williams
et al, 1998; Stoeber et al, 1999; Stoeber et al, 2002). Moreover, we
have shown that dysregulation of the DNA replication initiation
pathway is an early event in oesophageal carcinogenesis with
aberrant expression of MCM proteins occurring in both squamous
dysplasia and glandular dysplasia complicating Barrett’s oesopha-
gus (Going et al, 2002).
These data suggest that detection of MCM proteins in exfoliated
tumour cells might provide a potentially sensitive indicator of
oesophageal neoplasia. Here, we describe an evaluation of this
approach using a liquid phase immunofluorometric assay to
measure quantitatively Mcm5 levels in gastric luminal samples
obtained from patients undergoing gastroscopy for upper gastro-
intestinal symptoms. Gastric luminal secretions can be obtained
without the need for endoscopy, and can be collected in health
centres as a screening tool.
MATERIALS AND METHODS
Study subjects
Gastric aspirates were obtained from 40 patients undergoing
gastroscopy at Addenbrookes Hospital National Health Service
Trust (Cambridge, UK) for suspected or known oesophageal
carcinoma or symptoms of dyspepsia. All patients gave full
consent and the study was approved by the Local Research Ethics
Committee. Aspirates were obtained through the endoscope
suction channel. A full endoscopic examination of the oesophagus,
stomach and duodenum was performed. Endoscopies were
undertaken with conscious sedation using Midazolam. Punch
biopsies were taken from regions that looked abnormal to identify
any underlying pathological process. Aspirates were analysed in a
blinded manner for immunofluorometric Mcm5 detection. On
completion of the study, patient data were decoded and the
immunofluorometric signals compared with endoscopy and biopsy
histology results.
Gastric aspirates collection and storage
Prior to biopsy sampling, an endoscope was passed carefully down
the oesophagus, which was inflated with air thus minimising any
contact with the oesophageal surface. Gastric juice was then
aspirated immediately to reduce instrument-related trauma.
Gastric aspirates were kept on ice until processing for storage.
Storage buffer (10  phosphate-buffered saline (PBS), 5% bovine
serum albumin (BSA), 1 M sucrose, 0.2% NaN3) containing one
complete EDTA-free protease inhibitor cocktail tablet (Roche
Diagnostics Ltd, Lewes, East Sussex, UK) per 10ml of buffer was
added to gastric aspirates at one-tenth aspirate volume and
carefully mixed with the sample. Gastric aspirates in storage buffer
were transferred into 5ml cryovials and stored in liquid nitrogen
(LN2) for cryopreservation. The aspirates were stored in LN2
within 5h of the samples being collected.
Processing of standards and gastric aspirates
Standards for the immunofluorometric Mcm5 assay were pre-
pared, and standards and gastric samples processed as described
previously (Stoeber et al, 2002). Briefly, standards and clinical
samples were thawed, and the cells were isolated by centrifugation
at 1500g for 5min at 41C. The supernatants were discarded, and
the cell pellets were washed three times with 500ml of PBS. Cell
pellets were resuspended in 250ml (for those pellets with a volume
less than approximately 200ml) or 500ml (for those pellets with a
volume greater than approximately 200ml) of processing buffer
(PBS, 0.4% sodium dodecyl sulphate (SDS), 0.02% NaN3). Cell
lysates were prepared by incubating the resuspended samples at
951C for 45min. The DNA in each sample was sheared by passing
the lysates through a 21-gauge needle (Becton Dickinson UK Ltd,
Cowley, Oxford, UK), and nucleic acids were digested with DNase I
(20Uml
 1; Roche Diagnostics) and RNase A (1mgml
 1; Roche
Diagnostics) for 2h at 371C. The samples were centrifuged at
15000g for 10min to pellet the cell debris, the supernatants were
collected and 50ml of each was directly used in the immuno-
fluorometric assay.
Immunofluorometric measurement of Mcm5 levels in
gastric aspirates
Monoclonal antibodies (MAbs) 12A7 and 4B4 raised against His-
tagged human Mcm5 were protein A purified from hybridoma
supernatants as described previously (Stoeber et al, 2002). Protein
A-purified MAb 4B4 was labelled with europium using a DELFIA
s
Eu-labelling kit (Perkin-Elmer Life Science, Wallac Oy, Turku,
Finland) according to the manufacturer’s instructions. The assay
was standardised using HeLa cells as described previously (Stoeber
et al, 2002), and one fluorescence unit was defined as the signal
generated by the Mcm5 contents of one proliferating HeLa S3 cell,
approximately 10
5 Mcm5 molecules (Kearsey and Labib, 1998).
DELFIA
s research reagents were obtained from Perkin-Elmer Life
Science. All other reagents were obtained from Sigma-Aldrich.
Immunofluorometric measurements of Mcm5 levels were
performed as described previously (Stoeber et al, 2002). Standard
curves were constructed from fluorescence values generated by the
blank and standard wells, and the fluorescence values of the gastric
aspirate samples were calculated with the Multicalc Advanced
Immunoassay Data Management package (Perkin-Elmer Life
Science). For immunofluorometric measurement of Mcm5 levels,
assay standards, control samples and gastric aspirate samples were
run as duplicates and the mean of the duplicate results reported.
For acceptance of immunofluorometric measurements in the
assay, the following coefficients of variations were required: CV
o20% for results between 1500 and 5000 cellswell
 1 standard
curve points; CV o15% for results between 5000 and 15000
cellswell
 1; and CV o10% for results 415000 cellswell
 1.
Immunoassay performance
In our analysis, we used 1500 cellswell
 1 as the lower detection
limit because the within-batch coefficient of variation of the assay
was less than 25% in all samples with cell dilutions above 1500
cellswell
 1, but in only one-quarter of samples below this limit.
Samples that generated a fluorescence signal below that corre-
sponding to 1500 cellswell
 1 were reported as having fewer than
1500 cellswell
 1.
Immunohistochemistry
Formalin-fixed, paraffin-embedded surgical biopsy material from
tumour-positive cases was selected for immunohistochemical
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performed on a DAKO Techmatet 500 as described previously
(Stoeber et al, 2001). Primary antibodies were omitted in negative
controls and in addition appropriate tissue sections were used as
positive and negative controls. Microscopic images were acquired
with an Olympus BX51 light microscope/CCD camera set-up and
ANAlysis image capturing software (Soft Imaging Systems GmbH,
Mu ¨nster, Germany). A semi-quantitative determination of the
extent of staining was obtained by calculating a labelling index for
each protein stained. At least 200 nuclei were assessed per case.
Results were expressed as a percentage of positively stained nuclei
out of the total number of nuclei counted in representative
microscopic fields. The median and range of labelling indices were
calculated.
Statistical analysis
Sensitivity and specificity characteristics of the immunofluoro-
metric Mcm5 test for the detection of oesophageal cancer are
presented as a receiver operating characteristics (ROC) curve. The
area under the nonparametric ROC curve was used to assess the
overall accuracy of the test (McNeil and Hanley, 1984; Altman and
Bland, 1994). Three cut points were used to demonstrate test
performance under different circumstances as follows: at the lower
detection limit of the assay (i.e. 1500 cellswell
 1), where sensitivity
of the test was maximal; at the point where the false-positive and
false-negative rates of the test were equal (i.e. 5000 cellswell
 1);
and where specificity exceeded 95% (i.e. 7500 cellswell
 1). An
exact 95% confidence interval (CI) for each proportion, including
sensitivity, specificity and predictive values of Mcm5 and cytology,
was derived assuming a binomial distribution using StatXact
software, Version 4.0 (Cytel Software Corporation, Cambridge,
MA, USA). Unless otherwise stated, statistical tests were performed
using SPSS software, Version 11.5 (SPSS Inc., Chicago, IL, USA).
The level of the signal was compared between patient groups using
the Kruskal–Wallis test and for pairs of groups using the Mann–
Whitney U-test. All statistical tests were two-tailed, and a 5% level
was used to indicate statistical significance.
RESULTS
The patient characteristics, clinical symptoms on presentation,
endoscopy findings and histopathological diagnoses derived from
the 47 gastric aspirate samples were obtained for analysis (Table 1).
Table 1 Patient demographics and sample characteristics at endoscopy
and biopsy
Patient characteristics (n¼40 patients)
N (%) or median
(interquartile range)
Sex
Male 24 (60%)
Female 16 (40%)
Age (years) 74 (58–82)
Sample characteristics (n¼47 samples)
a
Gastric aspirate volume (ml) 4 (4–4.5)
Endoscopy and/or biopsy findings
Tumour absent 27 (57%)
Normal oesophagus 2
Diverticulum 1
Shatski ring 1
Chemical gastropathy 1
Oesophagitis
b 9
Barrett’s oesophagus without dysplasia 13
Tumour present 20 (43%)
AdCa
c 10
SCC 10
Tumour stage
T2N0M0 1
T3N0M0 9
T3N0M1 1
T3N1M0 1
T3N1M1 1
T4N1M0 1
AdCa¼adenocarcinoma; SCC¼squamous cell carcinoma.
aTwo samples from one
patient with AdCa, four samples from one patient and two samples from two
patients with SCC, and two samples from one patient with Barrett’s oesophagus with
associated inflammation and ulceration were included in the analysis.
bSeven patients
with oesophagitis had ulceration.
cThree AdCa’s had associated severely atypical
Barrett’s oesophagitis.
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Figure 1 ROC curve of immunofluorometric Mcm5 test. The jagged
curve (solid line) is the nonparametric ROC curve. The diagonal line is a
reference line. Area under curve¼0.93 (95% CI¼0.85–0.99). ROC
curves for detection of bladder cancer (jagged dotted line) and prostate
cancer (jagged dashed line) are shown for comparison.
Table 2 Sensitivity, specificity and predictive values of the Mcm5 test for
oesophageal cancer
a
Test
% Sensitivity
(95% CI)
% Specificity
(95% CI)
%P P V
(95% CI)
%N P V
(95% CI)
Mcm5 test X1500
cut point
95 (75–99) 48 (29–68) 58 (39–75) 93 (66–99)
Mcm5 test X5000
cut point
85 (62–97) 85 (66–96) 81 (58–95) 88 (70–98)
Mcm5 test X7500
cut point
75 (51–91) 96 (81–99) 94 (70–99) 84 (66–95)
Mcm5¼minichromosome maintenance protein 5; CI¼confidence interval;
PPV¼positive predictive value; NPV¼negative predictive value.
aThree cut-off
points were used to demonstrate test performance under different circumstances as
follows: at the lower detection limit of the assay (fluorescence signal generated from
1500 proliferating HeLa S3 cellswell
 1), where sensitivity of the test was maximal; at
the point where the false-positive and false-negative rates of the test were equal
(5000 cellswell
 1); and where specificity exceeded 95% (7500 cellswell
 1).
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follow-up. The patients’ median age was 74 years (range 40–90
years) and 60% were male. The 20 (43%) tumour samples
comprised 10 adenocarcinomas (AdCa) and 10 squamous cell
carcinomas (SCC). Three of the AdCas were found in association
with severely dysplastic Barrett’s oesophagus. A total of 13 patients
were diagnosed with metaplastic Barrett’s oesophagus without
associated dysplasia. Seven patients were found to have benign
ulceration in a background of inflammatory oesophagitis.
The performance of the immunofluorometric Mcm5 assay as a
diagnostic test for oesophageal cancer is shown as a ROC curve
(Figure 1). The test discriminated, with high specificity and
sensitivity, between patients with and without oesophageal cancer,
as demonstrated by the large area under the ROC curve (0.93 (95%
CI¼0.85–0.99)), which was statistically significantly larger than the
area predicted by the null hypothesis (0.5) (Po0.001). In other words,
a randomly selected patient with oesophageal cancer would have a
93% probability of having an immunofluorometric Mcm5 value that
is larger than a randomly selected patient without a malignancy.
Evaluation of the test is demonstrated in Table 2 at different
performance levels at cut-point values of 1500 cellswell
 1 (lower
detection limit of the assay), 5000 cellswell
 1 (equal false-positive
and false-negative rates) and 7500 cellswell
 1 (high specificity). At
the 1500-cell cut point, the test had 95% (19 of 20) sensitivity and
58% (19 of 33) positive predictive value. At the 5000-cell cut point,
the test had 85% (17 of 20) sensitivity and 81% (17 of 21) positive
predictive value. At the 7500-cell cut point, the test had 75% (15 of
20) sensitivity and 94% (15 of 16) positive predictive value.
Table 3 and Figure 2 show the performance of the immuno-
fluorometric Mcm5 test according to the diagnosis made at clinical
follow-up using endoscopy findings and histopathological
diagnosis as the gold standard. The level of signal in the four
Table 3 Immunofluorometric Mcm5 test performance in patient groups
Patient groups
and subgroups
Group
size (N)
Median
signal
Interquartile
range
% Signals X5000
(95% CI)
Negative for cancer 27 1718 o1500–2897 15 (4–34)
No ulceration 20 o1500 o1500–o2115 5 (1–25)
Ulceration 7 4871 2897–6732 43 (10–82)
Oesophageal cancer 20 16401 7263–29822 85 (62–97)
AdCa 10 11210 5023–23692 80 (44–97)
SCC 10 25036 9752–34221 90 (56–99)
Mcm5¼minichromosome maintenance protein 5; CI¼confidence interval;
AdCa¼adenocarcinoma; SCC¼squamous cell carcinoma.
Figure 3 Mcm2 protein expression in normal and neoplastic oesopha-
gus. (A) Normal squamous epithelium showing Mcm2 expression
restricted to the basal proliferative compartment. Onset of the differentia-
tion programme is associated with downregulation of the MCM replication
licensing factors. Mcm2 expression is undetectable in surface terminally
differentiated cells. (B) Nondysplastic testinal-type ‘specialised’ Barrett’s
mucosa showing Mcm2 expression in cells in the proliferative zone beneath
the mucosal surface. Mcm2 expression is markedly downregulated as cells
execute their differentiation programme and migrate onto the mucosal
surface. (C) Low- to high-grade squamous dysplasia showing high levels of
Mcm2 expression. The arrest in differentiation is associated with persistant
Mcm2 expression in surface layers. (D) Low-grade Barrett’s dysplasia
showing high levels of Mcm2 expression in upper crypts and surface layers.
The failure of dysplastic cells to execute their differentiation programme
(maturation arrest) is associated with persistent expression of the MCM
replication licensing factors in upper crypt and surface epithelium. (E)
Moderately to poorly differentiated SCC showing high levels of Mcm2
expression. Occasional viable Mcm2 negative cells are present showing
morphological features of differentiation (keratinisation). (F) Poorly
differentiated AdCa showing high levels of Mcm2 expression. Occasional
viable Mcm2-negative cells are also present showing some features of
glandular differentiation (mucin production).
No ulceration Ulceration AdCa SCC
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Figure 2 Mcm5 signal by sample group. Each box represents the
interquartile range of the Mcm5 signal data for the corresponding sample
group. The horizontal line inside the box represents the median signal. Any
signal further than 1.5 times the interquartile range is considered as an
outlying signal value and plotted separately. The dotted lines extend 1.5
times the interquartile range from the limits of the box.
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Po0.001). Interestingly, the Mcm5 immunofluorometric signal
for patients with ulceration (median 4871) was higher than for
other patients without malignancy, where the median signal was
below the lower detection limit of 1500 cellswell
 1 (Mann–
Whitney U-test, P¼0.002). The level of signal was not significantly
different (Mann–Whitney U-test, P¼0.16) between AdCas (med-
ian 11210) and SCCs (median 25036). The largest difference
(Mann–Whitney U-test, Po0.001) was between those samples
from patients without tumour (median 1718) and those with
tumour (median 16401).
The elevated levels of the Mcm5 DNA replication licensing
protein found in gastric aspirates from patients with oesophageal
cancer is consistent with our previous immunohistochemical
findings demonstrating aberrant expression of Mcm2 and Mcm5
proteins in dysplastic and malignant oesophageal lesions (Going
et al, 2002). Immunohistochemical analysis of the tumours
detected in this study confirms our previous findings showing
high levels of MCM protein expression, with the majority of
tumour cells expressing the Mcm2 and Mcm5 replication licensing
factors (SCCs: Mcm2 (92–98%, mean: 95%), Mcm5 (93–100%,
mean: 96%); AdCas: Mcm2 (83–99%, mean: 94%), Mcm5 (90–
98%, mean: 94%); Figure 3).
DISCUSSION
Patients with oesophageal cancer present at an advanced stage,
symptoms are usually of recent origin and their period of survival is
short. The incidence of oesophageal cancer is increasing and
therefore there is an urgent need for reliable cost effective methods
for early diagnosis (Wang et al, 1997). Abrasive brush cytology as a
screening technique for oesophageal cancer has been used for many
years in high incidence areas of China (Shu, 1983). Although the
brush biopsy capsule is inexpensive, the hidden costs including
preparation of slides and expert cytopathological assessment are
considerable. Moreover, despite the alarming increase in the
incidence of AdCa of the oesophagus in North America and Europe,
screening for neoplasia in Barrett’s oesophagus is controversial
partly due to the invasive nature and expense of introducing
endoscopic biopsy surveillance programmes (Wright et al,1 9 9 6 ) .
Maturation arrest and failure to engage correctly the differentia-
tion programme, the hallmark of dysplastic precancerous lesions,
is associated with aberrant expression of the MCM replication
initiation factors (Williams et al, 1998; Stoeber et al, 1999; Going
et al, 2002; Stoeber et al, 2002). Importantly, aberrant expression
of MCM proteins was identified in both squamous dysplasia and
Barrett’s glandular dysplasia, but not in Barrett’s metaplastic
oesophagus (Figure 3; Going et al, 2002). We have previously
shown that detection of MCM proteins in urine sediments is a
sensitive and specific test for urothelial neoplasia allowing
detection of bladder cancers at all stages and grades including
severe dysplasia/carcinoma in situ, the latter corresponding to a
similar step in tumour progression represented by dysplastic
Barrett’s oesophagus (Stoeber et al, 1999, 2002).
Using a similar analytical approach previously applied to the
genitourinary tract (Stoeber et al, 2002), application of the
immunofluorometric Mcm5 test to gastric aspirates has resulted
in a strikingly similar performance (Tables 2 and 3 and Figure 1).
Patients with tumours, including three cases with associated severe
dysplastic Barrett’s oesophagus, were detected with high sensitivity
(85–95% at the low cut-off point). Importantly, inflammatory
conditions including oesophagitis and Barrett’s metaplastic
oesophagus were not associated with false-positive results.
Interestingly, ulcerative lesions gave a signal, but with an
amplitude below that generated by tumours, most likely reflecting
reparative growth with exposure of the stem-transit compartment
to luminal secretions and the shedding of reactive Mcm5-positive
cells. Similar results were found in the urinary tract in relation to
renal calculi (Stoeber et al, 2002).
The immunofluorometric Mcm5 test provides a new approach
to the detection of oesophageal cancer. Given the magnitude in the
difference between Mcm5 levels in benign and malignant disease
found in this study, it is likely that even small cases at an early
stage will be detected. Studies on large unselected populations will
now be required to determine whether this novel diagnostic
approach can be exploited as a screening tool to detect early
curable tumours. Furthermore, our previous studies have shown
that aberrant expression of the MCM proteins is a powerful marker
of dysplasia in Barrett’s oesopagus (Going et al, 2002). These data
suggest that the immunofluorometric Mcm5 test could be further
refined for screening of Barrett’s oesophagus by employing balloon
cytology catheters, increasing the yield of cellular material for
biochemical analysis (Liu et al, 1994; Sepehr et al, 2000). The
sensitivity and specificity data are strikingly similar when
comparing oesophageal cancer with genitourinary tract cancers.
The areas under the ROC curve for oesophagus, bladder and
prostate are all around 0.93 (Figure 1; Stoeber et al, 2002). It is
likely that similar results will be obtained for other cancers arising
from self-renewing tissues using this approach.
These pilot data, including our previous studies examining the
expression profile of MCM proteins during oesophageal carcino-
genesis, suggest that immunofluorometric detection of Mcm5 in
gastric aspirates provides a new approach for the detection of
oesophageal neoplasia. Its use as a screening and diagnostic tool
for oesophageal neoplasia needs to be urgently investigated
considering the increasing incidence and high mortality rate
associated with this disease.
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